Elan Refused to Engage With Royalty Over Weekend, Chairman Says

Co. predicts “lengthy, and we think likely fruitless, effort to find a buyer willing to offer more than we are,” Royalty Pharma Chairman Rory Riggs says in letter today. * Elan has effectively been for sale for almost four months as a result of Royalty approach, Riggs says * If no buyer emerged in that time, it suggests none is interested at a price above Royalty’s offer, Riggs says.

Before it's here, it's on the Bloomberg Terminal.